Details for New Drug Application (NDA): 214559

✉ Email this page to a colleague

NDA 214559 describes DEFERASIROX, which is a drug marketed by Alkem Labs Ltd, Amneal, Annora Pharma, Aucta, Cipla, MSN, Norvium Bioscience, Teva Pharms Usa, Actavis Elizabeth, Alembic, Bionpharma, Glenmark Speclt, Sun Pharm, Zydus Pharms, Aurobindo Pharma Ltd, Chartwell Rx, Piramal, and Stevens J, and is included in thirty-two NDAs. It is available from twenty suppliers. Additional details are available on the DEFERASIROX profile page.

The generic ingredient in DEFERASIROX is deferasirox. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the deferasirox profile page.

Mechanism of Action	Cytochrome P450 1A2 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A4 Inducers Iron Chelating Activity

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
DEFERASIROX	deferasirox	GRANULE;ORAL	214559	ANDA	EPIC PHARMA, LLC	42806-371	42806-371-30	30 PACKET in 1 CARTON (42806-371-30) / 1 GRANULE in 1 PACKET
DEFERASIROX	deferasirox	GRANULE;ORAL	214559	ANDA	EPIC PHARMA, LLC	42806-372	42806-372-30	30 PACKET in 1 CARTON (42806-372-30) / 1 GRANULE in 1 PACKET

Active Rx/OTC/Discontinued:	RX	Dosage:	GRANULE;ORAL			Strength	90MG
Approval Date:	Mar 9, 2021	TE:	AB	RLD:	No

Active Rx/OTC/Discontinued:	RX	Dosage:	GRANULE;ORAL			Strength	180MG
Approval Date:	Mar 9, 2021	TE:	AB	RLD:	No

Active Rx/OTC/Discontinued:	RX	Dosage:	GRANULE;ORAL			Strength	360MG
Approval Date:	Mar 9, 2021	TE:	AB	RLD:	No

Complete Access Available with Subscription